Protein-protein interaction (PPI) inhibitors represent a vast class of therapeutic targets both intracellularly and extracellularly for a broad range of diseases, for instance cancer and HIV. The human interactome has been estimated to cover ~400,000 protein–protein interactions, making PPIs central to many biological processes, including enzymatic activity, assembly of protein complexes and subcellular localisation. However, PPIs are considered difficult to target. As a part of disease biological processes are often dysregulated, therefore PPIs have become an attractive target for therapy.

TargetMol’s PPI Inhibitor Library, a focused collection of 485 PPI-related compounds, can be used for research on protein-protein interaction.